CA3172689A1 - Cyclophilin inhibitors and uses thereof - Google Patents

Cyclophilin inhibitors and uses thereof Download PDF

Info

Publication number
CA3172689A1
CA3172689A1 CA3172689A CA3172689A CA3172689A1 CA 3172689 A1 CA3172689 A1 CA 3172689A1 CA 3172689 A CA3172689 A CA 3172689A CA 3172689 A CA3172689 A CA 3172689A CA 3172689 A1 CA3172689 A1 CA 3172689A1
Authority
CA
Canada
Prior art keywords
compound
organ
donor
injury
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172689A
Other languages
English (en)
French (fr)
Inventor
Ching-Pong Mak
Hans Fliri
Fashu MA
Michael Peel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farsight Medical Technology Shanghai Co Ltd
Original Assignee
Farsight Medical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Technology Shanghai Co Ltd filed Critical Farsight Medical Technology Shanghai Co Ltd
Publication of CA3172689A1 publication Critical patent/CA3172689A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3172689A 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof Pending CA3172689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020081296 2020-03-26
CNPCT/CN2020/081296 2020-03-26
PCT/CN2021/083015 WO2021190603A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3172689A1 true CA3172689A1 (en) 2021-09-30

Family

ID=77891508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172689A Pending CA3172689A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Country Status (9)

Country Link
US (1) US20230203099A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126903A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023518775A (cg-RX-API-DMAC7.html)
KR (1) KR20220158759A (cg-RX-API-DMAC7.html)
CN (1) CN115315432A (cg-RX-API-DMAC7.html)
AU (1) AU2021244763A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172689A1 (cg-RX-API-DMAC7.html)
TW (1) TW202144378A (cg-RX-API-DMAC7.html)
WO (1) WO2021190603A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CA2518265A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
AU2017267560B2 (en) * 2016-05-17 2022-03-24 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防

Also Published As

Publication number Publication date
AU2021244763A1 (en) 2022-10-06
EP4126903A1 (en) 2023-02-08
CN115315432A (zh) 2022-11-08
KR20220158759A (ko) 2022-12-01
EP4126903A4 (en) 2024-05-08
US20230203099A1 (en) 2023-06-29
TW202144378A (zh) 2021-12-01
JP2023518775A (ja) 2023-05-08
WO2021190603A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7776435B2 (ja) シクロフィリン阻害剤およびその使用
AU2021244763A1 (en) Cyclophilin inhibitors and uses thereof
US20250288639A1 (en) Treatment and prevention of nephrotoxin-induced kidney injuries
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
CA2909160A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
KR101949810B1 (ko) 설폰아마이드류 약학 조성물
WO2015111666A1 (ja) メガリン拮抗剤
KR20210148078A (ko) 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
HK40101696A (en) Treatment and prevention of nephrotoxin-induced kidney injuries
EA051978B1 (ru) Ингибиторы циклофилина и их применение
RU2017122329A (ru) Применение соединений ванадия для поддержания нормогликемии у млекопитающего
KR20090128479A (ko) 암 치료를 위한 경요도 절제술 후 방광내 아파지퀀 투여

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250331

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260506